Complement C5 Inhibitor Receives Priority Review by the FDA for Geographic Atrophy
On February 16, Iveric Bio announced in an announcement that the New Drug Application (NDA) for the complement C5 inhibitor Zimura (avacincaptad pegol, ACP) for the treatment of age-related macular degeneration (AMD)Read More…